永安药业(002365) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥171,153,602.96, a decrease of 12.96% compared to ¥196,644,532.11 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥4,367,181.24, representing a decline of 115.23% from a profit of ¥28,680,093.28 in the previous year[5] - The company's basic earnings per share were -¥0.0151, a decrease of 115.52% from ¥0.0973 in the same period last year[5] - The company reported a net profit of CNY 5,189,100.12, compared to CNY 6,293,983.84 in the previous period, reflecting a decrease of 17.57%[19] - The company reported a net loss of CNY 6,693,941.24, compared to a net profit of CNY 28,476,157.30 in the previous period, indicating a significant decline in profitability[20] - Operating profit decreased to CNY -7,610,730.54 from CNY 34,147,399.94, reflecting a substantial drop in operational performance[20] - The total comprehensive income attributable to the parent company was CNY -4,377,798.76, compared to CNY 26,719,061.16 in the prior period, indicating a significant decline[21] - The company incurred a total profit before tax of CNY -7,790,952.05, compared to CNY 33,833,677.38 in the previous period, highlighting a significant downturn[20] Cash Flow and Liquidity - The net cash flow from operating activities increased significantly to ¥24,701,934.36, compared to a negative cash flow of ¥4,904,038.98 in the same period last year, marking a 603.71% improvement[5] - Cash flow from operating activities generated a net inflow of CNY 24,701,934.36, a recovery from a net outflow of CNY -4,904,038.98 in the prior period[21] - The net cash flow from investing activities was -¥108,342,211.78, an increase in outflow of 93.54% compared to -¥55,978,437.10 in the previous year[9] - The company experienced a net cash outflow from investing activities of CNY -108,342,211.78, worsening from a net outflow of CNY -55,978,437.10 in the previous period[22] - Cash and cash equivalents decreased to CNY 211,651,545.97 from CNY 320,405,292.96, a decline of 33.94%[15] - The cash and cash equivalents at the end of the period decreased to CNY 211,651,545.97 from CNY 229,945,727.87, indicating a decline in liquidity[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,255,583,809.39, down 2.30% from ¥2,308,602,905.85 at the end of the previous year[5] - Total assets decreased to CNY 2,255,583,809.39 from CNY 2,308,602,905.85, a reduction of 2.29%[17] - Total liabilities decreased to CNY 235,624,782.19 from CNY 266,545,677.53, a decline of 11.59%[16] - The company’s total equity attributable to shareholders decreased by 0.99% to ¥1,974,121,739.64 from ¥1,993,780,889.08 at the end of the previous year[5] - The company’s total equity decreased to CNY 2,019,959,027.20 from CNY 2,042,057,228.32, a decrease of 1.09%[17] - The company’s short-term borrowings decreased to CNY 29,500,000.00 from CNY 39,526,078.47, a reduction of 25.66%[16] Shareholder Information - The total number of common shareholders at the end of the reporting period is 22,971[10] - The largest shareholder, Chen Yong, holds 21.54% of the shares, amounting to 63,468,000 shares[10] - The top ten shareholders include both individual and corporate entities, with the largest corporate shareholder being Huanggang Yong'an Pharmaceutical Co., Ltd. at 3.57%[10] - The company has completed a share buyback program, repurchasing 5,537,350 shares, which is 1.88% of the total share capital, with a total expenditure of 40,454,553.49 RMB[11] - The company plans to use the repurchased shares for employee stock ownership plans or equity incentive plans[11] - The maximum buyback price was adjusted to 7.90 RMB per share, effective from July 5, 2024[11] Operational Developments - The company is currently involved in a patent infringement lawsuit, with a favorable ruling received in February 2024, stating no infringement on the claimed patents[12] - The company is actively monitoring the bankruptcy proceedings of the plaintiff in the patent case to protect its interests[12] - The company is in the final stages of expanding its production capacity for taurine food additives to 40,000 tons per year, with an investment of 250 million RMB[13] - A new wholly-owned subsidiary, Fuweile Pet Food (Wuhan) Co., Ltd., has been established with a registered capital of 2 million RMB[14] Expenses - The company’s management expenses decreased by 32.34% to ¥15,216,294.82 from ¥22,488,466.54 in the previous year[8] - Total operating costs increased to CNY 184,150,029.42, up 5.49% from CNY 175,009,541.52 in the previous period[19] - Operating costs included CNY 154,528,544.00 in cost of goods sold, which rose from CNY 140,270,981.04, indicating a 10.16% increase[19] - Research and development expenses were CNY 8,417,652.08, down 16.01% from CNY 10,019,915.12 in the previous period[19] - The company reported a significant increase in financial asset fair value changes, with a loss of ¥2,371,888.97 compared to a gain of ¥3,122,732.45 in the previous year, a change of 175.96%[8]